Please login to the form below

Not currently logged in
Email:
Password:

Cervical cancer vaccination rates lower than expected in Europe

ECDC updates guidance advising all girls in EU are immunised

Uptake of cervical cancer vaccines in many European countries is falling short of expectations, says the European Centre for Disease Prevention and Control (ECDC) and it's calling on countries with poor coverage to increase their vaccination campaigns.

The EU agency, which was set up in 2005 to provide support and advice on the treatment of infectious diseases in Europe, said that since the introduction of vaccination programmes in 19 European countries over the past four years, only two had vaccination coverage rates above 80 per cent for their target age range of those that reported such data.

Countries to perform particularly poorly in administering the three doses to its recommended age group include Luxembourg, with 17 per cent coverage, France with 24 per cent and Slovenia with 55 per cent.

At the other end of the scale, Portugal managed 84 per cent coverage, the UK had 80 per cent and Denmark had 79 per cent in their efforts to immunise girls from the human papillomavirus (HPV), a leading cause of cervical cancer.

The ECDC suggested that some deterring factors for low uptake of the vaccine included the high cost of the two vaccines available, GlaxoSmithKline's Cervarix and Merck & Co's Gardarix, as well as the three-dose regime.

Also mentioned as a problem was parental acceptance of the vaccine, with girls requiring permission to be vaccinated due to their young age.

This has led to an increased push from the ECDC to bolster countries' vaccination efforts, and it advises that all girls in Europe should have the cervical cancer vaccine by the age of 14 in a new update to its HPV vaccine guidance.

ECDC director Marc Sprenger said: “We, public health authorities, frontline healthcare workers and parents alike, have a shared responsibility to protect thousands of women from cervical cancer.

“We need to work together to ensure that all girls between 10 and 14 years of age are vaccinated. European countries may need to examine why HPV vaccination coverage rates in their countries are not higher and strengthen their vaccination campaigns accordingly.”

The updated guidance also address the issue of boys receiving the HPV vaccine, with the ECDC commenting that, despite similar efficacy efforts for the quadrivalent HPV vaccine as demonstrated in girls, the personal benefit of the vaccine for men in terms of cancer prevention is very low.

This would likely lead to low vaccination coverage, meaning a vaccination regime for to protect against HPV in boys would not be a cost-effective option.

Read the updated ECDC guidance on HPV vaccination in Europe

 

5th September 2012

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Biosector 2

Biosector 2 (B2) is a global healthcare public relations agency that partners with visionary clients to deliver groundbreaking programs and...

Latest intelligence

When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....
Forecasting for Licensed Compounds
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharmaceutical forecasting...

Infographics